| Project/Area Number |
24591037
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
OZAWA Takuya 新潟大学, 医歯学系, 助教 (70467075)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOBA Ken 新潟大学, 医歯学総合病院, 講師 (60313540)
HANAWA Haruo 新潟大学, 医歯学系, 准教授 (40282983)
ODA Masato 新潟大学, 医歯学総合病院, 医員 (60572724)
YANAGAWA Takao 新潟大学, 医歯学総合病院, 特任助教 (10625586)
MORIYAMA Masato 新潟大学, 医歯学系, 助教 (30598131)
MASUKO Masayoshi 新潟大学, 医歯学総合病院, 准教授 (70397115)
SUDA Masayoshi 新潟大学, 医歯学総合病院, 医員 (70714509)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 臨床心血管病態学 / 血管再生 / 赤芽球 / 細胞療法 / 体外増幅 / 細胞移植 / 血管新生治療 / 体外培養 |
|---|
| Outline of Final Research Achievements |
We investigated the efficacy of a novel cell therapy by implantation of ex vivo expanded immature erythroblasts cultured from hematopoietic stem/precursor cells. 13 patients with severe chronic limb ischemia accompanied by peripheral artery disease, Burger's disease or collagen arteritis were enrolled in a pilot clinical trial of the novel cell therapy by transplantation of ex-vivo expanded immature erythroid cells (EVEETA). In the clinical trial, most clinical symptoms such as rest pain and skin ulcers improved in 4 weeks, and did not recur in the one-year follow-up. A small amount of bone marrow (mean amount, 71.2 ± 20.1 mL) was collected from the patients under local anesthesia. After 14 days of culture, the number of erythroblasts increased to enough level for in vivo angiogenesis therapy (64.5 ± 41.3 times from baseline). No adverse events were observed in any of the patients.
|
